Literature DB >> 31242370

Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

Robert J Motzer1, Bo Huang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31242370     DOI： 10.1056/NEJMc1905518

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.

Authors:  Sei Naito; Tomoyuki Kato; Kazuyuki Numakura; Shingo Hatakeyama; Tomoyuki Koguchi; Shuya Kandori; Yoshihide Kawasaki; Hisanobu Adachi; Renpei Kato; Shintaro Narita; Hayato Yamamoto; Soichiro Ogawa; Sadafumi Kawamura; Wataru Obara; Akihiro Ito; Hiroyuki Nishiyama; Yoshiyuki Kojima; Chikara Ohyama; Tomonori Habuchi; Norihiko Tsuchiya
Journal:  Int J Clin Oncol       Date:  2021-06-30       Impact factor: 3.402

2.  Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.

Authors:  Andras Bibok; Rahul Mhaskar; Rohit Jain; Jingsong Zhang; Jessica Frakes; Sarah Hoffe; Ghassan El-Haddad; Nainesh Parikh; Altan Ahmed; Mayer N Fishman; Junsung Choi; Bela Kis
Journal:  Cardiovasc Intervent Radiol       Date:  2021-07-26       Impact factor: 2.740

Review 3.  Natural history of untreated kidney cancer.

Authors:  Kristen McAlpine; Antonio Finelli
Journal:  World J Urol       Date:  2021-02-16       Impact factor: 4.226
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.